替格瑞洛联合常规治疗对冠心病不稳定型心绞痛患者的疗效及对心功能的影响

Efficacy of ticagrelor combined with routine therapy on coronary heart disease complicated by unstable angina pectoris and its effect on cardiac function

目的研究替格瑞洛联合常规治疗对冠心病不稳定型心绞痛患者的疗效。方法抽取2019年12月至2021年10月河南省第二人民医院收治的冠心病不稳定型心绞痛患者84例,按随机数字表法分为替格瑞洛组与常规用药组,每组42例。常规用药组采用常规治疗,替格瑞洛组在常规用药组基础上加用替格瑞洛治疗。对比两组疗效、炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平、血小板聚集率(MPA)、N末端B型钠尿肽原(NT-proBNP)、心绞痛发作次数和持续时间、不良反应发生率。结果替格瑞洛组总有效率(95.24%,40/42)高于常规用药组(80.95%,34/42),P<0.05。治疗后,替格瑞洛组IL-6、TNF-α、MPA、NT-proBNP水平均低于常规用药组(P均<0.05);替格瑞洛组心绞痛发作次数少于常规用药组,持续时间短于常规用药组(P<0.05)。替格瑞洛组不良反应发生率(7.14%,3/42)与常规用药组(9.52%,4/42)比较差异未见统计学意义(P>0.05)。结论替格瑞洛联合常规治疗有利于提高冠心病不稳定型心绞痛患者的治疗效果,缓解炎症反应,抗血小板聚集、改善心功能,并可改善心绞痛发作情况。

Objective To study the efficacy of ticagrelor combined with routine therapy in the treatment of coronary heart disease complicated by unstable angina pectoris.Methods A total of 84 patients with coronary heart disease complicated by unstable angina pectoris treated in the Second People’s Hospital of Henan Province from December 2019 to October 2021 were selected and divided into a ticagrelor group and a routine medication group according to random number table method,with 42 cases in each group.The routine medication group was treated with routine treatment,and the ticagrelor group was treated with ticagrelor based on the treatmene of the routine medication group.The curative effect,inflammatory factors including interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),platelet aggregation rate(MPA),N-terminal B-type natriuretic peptide(NT-proBNP),the number and duration of angina pectoris and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the ticagrelor group was 95.24%(40/42),which was higher than that of routine medication group(80.95%,34/42),P<0.05.After treatment,the levels of IL-6,TNF-α,MPA and NT-proBNP in the ticagrelor group were lower than those in the routine medication group(P<0.05).The frequency of attacks of angina pectoris in the ticagrelor group was less the that in the routine medication group,and duration of angina pectoris in the ticagrelor group were ohorter than that in the routine medication group(P<0.05).There was no significant difference in the incidence of adver reactions between the ticagrelor group(7.14%,3/42)and the routine drug group(9.52%,4/42),P>0.05.Conclusions Ticagrelor combined with routine therapy in the treatment of coronary heart disease complicated by unstable angina pectoris is helpful to improve the curative effect,alleviate inflammation,resist platelet aggregation,improve cardiac function,and improve the attack of angina pectoris.